UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients - Concepedia

Concepedia

Publication | Open Access

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

DOI Full Paper Access

48

Citations

29

References

2022

Year

Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit Deiman, Jesse J. Swen, Saskia Houterman, Stijn L.W. Koolen, Sander Bins, Anna M.J. Thijs,

European Journal of Cancer

Drug SafetyProspective SafetyPoor Metaboliser PatientsMedicineGenotype-guided DosingPharmacotherapyPharmacogenomicsPharmacology

References

	Year	Citations

Page 1

Page 1